Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.41 |
| ▸ | LOX | P28300 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20929520 | 0.82 | LMNA (0.49) | KMT2ALMNAL3MBTL1MEN1LOXL2 | |
| SCHEMBL20929533 | 0.75 | EPHX2 (0.67) | KMT2ALMNAL3MBTL1TDP1MEN1 | |
| SCHEMBL17410524 | 0.74 | LMNA (0.61) | KMT2ALMNAL3MBTL1TDP1MEN1 | |
| SCHEMBL20929556 | 0.74 | L3MBTL1 (0.45) | KMT2ALMNAL3MBTL1TDP1MEN1 | |
| SCHEMBL24604285 | 0.73 | L3MBTL1 (0.63) | KMT2ALMNAL3MBTL1TDP1MEN1 | |
| SCHEMBL13231429 | 0.73 | ENPP2 (0.54) | LMNAPTGS2 | |
| SCHEMBL28725053 | 0.72 | PTGS2 (0.41) | KMT2AL3MBTL1TDP1MEN1LOXL2 | |
| SCHEMBL3536702 | 0.71 | KMT2A (0.56) | KMT2ALMNAL3MBTL1TDP1MEN1 | |
| SCHEMBL23352198 | 0.70 | ADRB2 (0.47) | KMT2ALMNAL3MBTL1TDP1MEN1 | |
| SCHEMBL23352202 | 0.70 | PTGS2 (0.40) | KMT2ALMNAMEN1LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459321-B2 | Broad spectrum antiviral compositions and methods | EVRYS BIO, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210139475-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459321-B2 | Broad spectrum antiviral compositions and methods | IRF3, MAVS, ZC3HAV1 | KMT2A 2059/4885LMNA 2718/4885L3MBTL1 3947/4885 |
| US-20210139475-A1 | Broad Spectrum Antiviral Compositions and Methods | MAVS, IRF3, ZC3HAV1 | KMT2A 2333/4885LMNA 3185/4885L3MBTL1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.